Trusted Resources: Evidence & Education
Scientific literature and patient education texts
131I-Induced Graves’ Disease in Patients Treated for Toxic Multinodular Goitre: Systematic Review and Descriptive Analysis
source: Journal of Endocrinological Investigation
year: 2018
authors: Roque C, Vasconcelos CA
summary/abstract:Background:
Graves’ disease (GD) arising after the treatment of toxic multinodular goitre (TMNG) with radioiodine has long been described but it remained unclear whether GD was in fact iodine induced, its incidence, risk factors, natural history and treatment outcomes. Methods: A systematic search using The Cochrane Library, Medline and PubMed Central allowed the pooling of data from 3633 patients with thyroid autonomy, 1340 patients with TMNG, to fill gaps in knowledge, regarding the clinical expression of iodine-induced GD (131I-IGD) in adults.
Results:
131I-IGD developed in 0–5.3% of those with thyroid autonomy (first year) and in 5–5.4% of those with TMNG, 3–6 months after treatment. Patients with toxic adenoma were less affected. 131I-IGD was more common in patients with pre-treatment direct or indirect signs of autoimmunity: positive anti-TPO (p < 0.05), glandular hypoechogenicity, TRAbs within reference range, diffuse uptake on 99mTc-pertechnetate scans (p < 0.05), findings that may increase the risk tenfold. 131I-IGD manifested 3 months after 131I, justifying 15.4–29% of cases of relapse. The rate of spontaneous remission was 17–20% (6 months) and the rate of relapse after a second 131I treatment 22–25%. The use of an uptake-based administered 131I activity led to a greater proportion of euthyroid patients (78% compared to 25–50% with the mass-based approach).
Conclusions:
GD may be triggered by 131I. The incidence of the condition is low. Several risk factors were consistently identified; some have shown to raise the risk significantly. 131I-IGD seems more treatment resistant than iodine-independent GD and the best resolution rates were achieved with uptake-based selected iodine activities.
DOI: 10.1007/s40618-018-0827-y
read more
myBinderRelated Content
-
Quality of Life Is Worse at 6-10 Years after Radioactive Iodine Treatment of Graves’ Disease as Compared with Anti...Background: Graves’ disease is a comm...
-
TSH-Receptor Autoimmunity in Graves’ Disease After Therapy With Anti-Thyroid Drugs, Surgery, or Radioiodine: A...Introduction: Autoimmunity against the ...
-
Radioactive Iodine Can Be First-Line for Hyperthyroidism, Says UKNew UK guidelines for the treatment of h...
-
Back on Track: 3 Time Olympic Gold Medalist Gail Devers’ StoryBlink and you just might miss the fastes...
-
Graves’ Disease Pharmacotherapy in Women of Reproductive AgeGraves' disease is an autoimmune disorde...
-
Relation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
-
Risk Factors For Developing Thyroid-Associated Ophthalmopathy Among Individuals with Graves’ DiseaseImportance: Thyroid-associated ophthalm...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google